Predict your next investment

HEALTHCARE | Biotechnology
abxis.com

See what CB Insights has to offer

Founded Year

2001

Stage

IPO | IPO

About ISU Abxis

ISU Abxis is a biopharmaceutical company specializing in the development of manufacturing of therapeutic proteins, with special focus on monoclonal antibodies. Its strategy to position ISU Abxis in the market of therapeutic antibodies starts from the analysis of the unmet needs of therapeutics in the market, with the goal of providing effective medicines to fulfill these unmet needs, ultimately contributing to the improvement of the quality of life.

ISU Abxis Headquarter Location

5th fl. Global R&D Center Building C 22 Daewangpangyoro 712-beongil Bundang-gu Seongnam-si

Gyeonggi-do, 13488,

South Korea

+81 316964700

Latest ISU Abxis News

Korean biotech firms hire foreign scientific advisors for global commercialization

Jul 27, 2021

닫기 Korean biotech companies are increasingly establishing a scientific advisory committee to speed up global new drug development and enhance R&D capabilities. An advisory group of experts can help the entire new drug development cycle, including developing new pipelines, discovering candidate substances, and designing clinical trials. Also, they can help local companies contact overseas regulatory agencies and clinical researchers for clinical studies. On July 20, SillaJen announced that it would launch Scientific Advisory Board (SAB) directly under the CEO to strengthen new drug research, development, and clinical study capabilities. In addition, the company said it scouted renowned oncologists, Dr. Steve Morris from St. Jude Children’s Research Hospital, and Dr. Howard Kaufman from Harvard Medical School. Dr. Morris is an eminent oncologist who studied oncology at St. Jude Children’s Research Hospital for 25 years, lauded for discovering the mechanism of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) and helping ALK inhibitors – such as Pfizer's Xalkori (ingredient: crizotinib), Novartis' Zykadia (ceritinib), Roche’s Alecensa (alectinib) and Takeda's Alunbrig (brigatinib) – reach the market. Dr. Kaufman, a melanoma expert, led a pivotal study of Imlygic, the world’s first oncolytic viral therapy. He is researching and conducting clinical trials on melanoma treatments at the Massachusetts General Hospital. SillaJen said its SAB would advise in all drug development processes, including the clinical trial of Pexa-Vec and studies of a new candidate introduced by Greenfire Bio, a subsidiary of M2N, the acquirer of SillaJen. On July 8, Isu Abxis launched a scientific advisory committee to expedite the development of immunotherapy. According to Isu Abxis, two experts joined the advisory group -- Dr. Bernards René, a scholar in cancer stem cell research at the Netherlands Cancer Institute, and Christophe Quéva, Chief Scientific Officer of Oncorus. The company is also pushing to bring a scholar at the Bloomberg-Kimmel Institute for Cancer Immunotherapy of the Johns Hopkins University School of Medicine. Isu Abxis said its SAB, consisting of experts who have led various research and clinical development and commercialization strategies in immuno-oncology in the U.S. and Europe, will boost R&D to treat cancer and incurable diseases using antibody technology. In November, Vigencell, an affiliated company of Boryung Pharmaceutical, set up a scientific advisory committee composed of immunology and clinical research experts. The advisory committee consists of three experts in Vigencell's platform technology and clinical research. Vigencell’s scientific advisory committee members are (from left) Esteban Celis, a professor at Georgia Augusta University, Suzanne Ostrand Rosenberg, a professor at the Huntsman Cancer Institute of the University of Utah, and Moon Han-lim, CEO of Connect Clinical Sciences. Vigencell’s advisory team includes Esteban Celis, a professor at Georgia Augusta University. He previously worked as a reviewer at the National Institutes of Health and a professor at Mayo Clinic in Minnesota. The committee also includes Suzanne Ostrand Rosenberg, a professor at the Huntsman Cancer Institute of the University of Utah. She is a scholar in immunology related to bone marrow-derived suppressor cells. Moon Han-lim, CEO of Connect Clinical Sciences, who previously worked as oncology medical director for Asia at GSK, is also a member of the advisory committee. Legochem Biosciences and ABL Bio also operate scientific advisory committees. Then, why do companies get advice from advisory committees rather than directly hire new drug developers? Park Sang-ho, executive vice president at Isu Abxis, said it was inefficient to secure global competitiveness with internal staff. “We will expand open innovation activities and the SAB members to go beyond research and achieve commercialization,” he said. His comments hint that companies are attempting to boost new drug development capabilities with external advice rather than directly hiring professionals, raising costs. A company official said scientific advisory board members “get rewarded” but declined to elaborate. Another company official said companies provide “a kind of consulting fee” for them. Companies that recently added scientific advisory panels all work on innovative drugs or new drug development platforms in oncology or incurable diseases. SillaJen is developing an oncolytic virus therapy Pexa-Vec, and Isu Abxis, an anticancer drug Beracetamab (code name: ISU104). Vigencell is also developing treatments for intractable diseases, including ViTier, a patient-customized tumor-targeted killer T cell treatment. Companies operating scientific advisory committees said the greatest advantage of having the advisory group was that they could obtain know-how on commercializing the product in foreign markets. “I’ve been conducting local R&D so far, and it is true that we don’t have much experience in global commercialization,” an official at a biotech company said. “Those who joined the scientific advisory committee have rich experience in commercialization and R&D. So, we expect that we can get help in all cycles, including clinical design and activation of a clinical test site.”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

ISU Abxis Patents

ISU Abxis has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Experimental cancer drugs
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/2/2016

9/17/2019

Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Transcription factors, Clusters of differentiation

Grant

Application Date

11/2/2016

Grant Date

9/17/2019

Title

Related Topics

Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Transcription factors, Clusters of differentiation

Status

Grant

ISU Abxis Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ISU Abxis Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.